Clinical Trial Update: Combined aPproach to Treatment Using Ranibizumab and Efalizumab for Diabetic Macular Edema Study: The CAPTURE DME Study [Phase 1]

View source ↗

Summary

Phase 1 CAPTURE DME trial investigating ranibizumab with efalizumab for diabetic macular edema has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Macular Edema

Drugs mentioned

• Lucentis (ranibizumab)
• Raptiva (efalizumab)

Snippet

Sponsor: Johns Hopkins University | Conditions: Diabetic Macular Edema | Phase 1 | Status: WITHDRAWN